7 terminated. 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Terminated 7 |
Follow Refractory Diffuse Large B-Cell Lymphoma: new trials by email Literature Review of Refractory Diffuse Large B-Cell Lymphoma trials Research Report on Refractory Diffuse Large B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | Roswell Park Cancer Institute | 1 | 2024-11-26 | 2025-08-03 |
| A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies BGB-21447 - Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Phase 1 | Terminated | BeOne Medicines | 51 | 2023-06-20 | 2026-07-14 |
| Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma Copanlisib, Gemcitabine, Carboplatin - Grade 3b Follicular Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | University of Washington | 12 | 2020-03-31 | 2023-06-29 |
| Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma Nivolumab, Rituximab, Lenalidomide - Recurrent Central Nervous System Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | Vanderbilt-Ingram Cancer Center | 6 | 2018-06-14 | 2019-04-25 |
| huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes, Cyclophosphamide, Fludarabine - Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 55 | 2017-11-03 | 2024-04-10 |
| A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma 400mg ABT-199, Ibrutinib, Rituximab - Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | Hackensack Meridian Health | 10 | 2017-09-05 | 2024-09-23 |
| JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014, Cyclophosphamide, Durvalumab - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 30 | 2016-11-15 | 2022-08-24 |
Lymphoma, Large B-Cell, Diffuse (7) · Lymphoma, Follicular (3) · Lymphoma, Non-Hodgkin (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Burkitt Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Mantle-Cell (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Hemic and Lymphatic Diseases (7) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Lymphatic Diseases (7) · Lymphoma (7) · Lymphoproliferative Disorders (7) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Lymphoma, B-Cell (6) · Lymphoma, Non-Hodgkin (4) · Hematologic Diseases (3) · Leukemia (3) · Leukemia, Lymphoid (3) · Chronic Disease (2) · Disease Attributes (2)
Cyclophosphamide (3) · Rituximab (3) · Leukapheresis (2) · fludarabine (2) · fludarabine phosphate (2) · Biopsy (1) · CT-P10 (1) · Calcium Dobesilate (1) · Carboplatin (1) · Dexamethasone (1) · Disulfides (1) · Gemcitabine (1) · Immunoglobulin G (1) · Lenalidomide (1) · Magnetic Resonance Spectroscopy (1)
Fred Hutchinson Cancer Center (2) · BeOne Medicines (1) · Hackensack Meridian Health (1) · Roswell Park Cancer Institute (1) · University of Washington (1) · Vanderbilt-Ingram Cancer Center (1)
United States (7) · Australia (1) · China (1) · New Zealand (1)
Jordan Gauthier (2) · Andre Goy, MD (1) · Francisco J Hernandez-ILizaliturri (1) · Nishitha Reddy, MD (1) · Ryan Lynch (1)
PMID 34515338, PMID 37903325, PMID 39820359
2025 (1), P30CA015704 (1), R01CA136551 (1)